HEMATOLOGIC MALIGNANCIES GENERAL
The P377-A1 MLPA probemix is intended for screening DNA samples derived from blood or bone marrow for the most common and diagnostically significant copy number changes associated with hematologic malignancies, including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic lymphoid leukaemia (CLL), chronic myeloid leukaemia (CML), myelodysplastic syndrome (MDS) and various lymphomas. This kit is intended to be used in combination with karyotype analysis. Suggestions on MLPA probemixes that can be used to confirm results or to get a better resolution on genes or chromosomal areas of interest can be found in Table 2.
The P377-A1 probemix contains probes for several genes and chromosomal regions known to have a diagnostic or prognostic significant role in hematologic malignancies: 2p (MYCN and ALK), 5q (MIR145, EBF1 and MIR146A), 6q, 7p12 (IKZF1), 7q, 8q24 (MYC), 9p (JAK2 V617F mutation, MTAP, CDKN2A, CDKN2B and PAX5), 10q23 (PTEN), 11q23 (ATM), 12p (ETV6), 12q, 13q (RB1, MIR15A, DLEU2, DLEU1), 17p (TP53), 17q, Chr 18 and Chr 19, 21q (RUNX1).